



## **Lantheus Holdings to Host Fourth Quarter and Full Year 2015 Earnings Conference Call and Provide 2016 Guidance on February 22, 2016 at 4:30 p.m. Eastern Time**

February 8, 2016

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 8, 2016-- [Lantheus Holdings, Inc.](#) (the "Company") (NASDAQ:LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), today announced that it will host a conference call at 4:30 p.m. ET on Monday, February 22, 2016, to discuss its financial and operating results for the fourth quarter and full year of 2015. The Company will also provide guidance for 2016.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 42121023. A live audio webcast of the call also will be available on the homepage of the Company's website at [www.lantheus.com](http://www.lantheus.com).

A replay of the telephone conference call and audio webcast will be available from approximately 8:30 p.m. ET on February 22, 2016 through midnight on March 7, 2016. To access a replay of the conference call, dial 1-855-859-2056 (U.S. callers) or 1-404-537-3406 (international callers), and provide passcode 42121023.

### **About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.**

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. ("LMI"), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI's key products include the echocardiography contrast agent DEFINITY<sup>®</sup> Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechnoLite<sup>®</sup> (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico, Canada and Australia. For more information, visit [www.lantheus.com](http://www.lantheus.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160208006391/en/>

Source: Lantheus Holdings, Inc.

Lantheus Holdings, Inc.  
Meara Murphy, 978-671-8508